drugset / Trial / NCT00387907

Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer

NCT00387907 ↗

Phase 2 Completed 6 enrolled Sanofi
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the anti-tumor activity of the combination of experimental drug (larotaxel) when combined with Herceptin® in patients with advanced breast cancer. Anti-tumor activity will be determined by looking at changes in tumor size on CT or MRI scans. Additional goals of this study are to look at patient safety, to determine how long the study drugs (larotaxel and Herceptin®) stay in the patient's body and what effects the study medications may have on each other, and to find out how long patients remain cancer free on this study treatment.

Timeline

Start
2006-10
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Trastuzumab Monoclonal antibody — Intravenous
Subject larotaxel Small molecule — Intravenous

Indications